Sharemaestro company-news research for Qiagen N.V. (QIA), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.

GER Germany Measured evidence

Company news sentiment

QIA news sentiment

Qiagen N.V.

Company headlines compared by relevance, subject, source independence, tone and the market's completed price response.

Weighted tone63Neutral is 50
Constructive news tone 52/100 evidence confidence 100% direct company focus 2 current stories across 1 publishers
Latest weekly closeEUR 36.46week of 7 Aug 2026
Dominant catalystEarnings75/100 classification confidence
News data statusHealthy0 duplicate stories removed

Current company news

News confirmed by price

Constructive news tone is drawn from 2 fresh independent stories, including 2 company-specific items across 1 publishers.

Latest source headline QIAGEN Receives U.S. FDA Clearance for First QIAstat-Dx Bloodstream Infection Panel finance.yahoo.com · 10 Aug 2026 20:05

What supports the read

Direct evidence

2 current stories are mapped specifically to QIA.

Narrative agreement

Cross-story agreement is 99/100, indicating a comparatively coherent tape.

Price response

Constructive news tone is being confirmed by positive weekly price action.

What tempers the read

Source breadth

Only 1 publisher currently contribute to the measured read.

63/100
Weighted toneConstructive news tone
52/100
Evidence confidencebuilding confidence
100%/100
Company focus2 direct stories
99/100
Evidence agreement1/100 dispersion

News history

Tone and story flow over 21 days

Daily weighted evidence
10 Aug: 2 stories 10 Aug: tone 77, 2 stories 95505
24 Jul03 Aug13 Aug
Weighted toneStory volumeNeutral 50

Evidence confidence

What supports the score

Measured separately from tone

Confidence rises through sample depth, independent publishers, direct company relevance, freshness and agreement. A high or low tone score is not itself evidence of reliability.

Sample depth25
1.97 effective stories
Source breadth20
1 independent publishers
Direct relevance100
company-specific evidence share
Freshness65
recency-weighted evidence
Agreement99
cross-story consistency
Source independence0
lower publisher concentration

Price context

Sentiment against the 26-week price path

News confirmed by price

Constructive news tone is being confirmed by positive weekly price action.

13 Feb 2026: close 43.28, indexed 100.020 Feb 2026: close 40.99, indexed 94.727 Feb 2026: close 41.96, indexed 97.006 Mar 2026: close 39.1, indexed 90.313 Mar 2026: close 36.03, indexed 83.320 Mar 2026: close 34.8, indexed 80.427 Mar 2026: close 33.95, indexed 78.403 Apr 2026: close 35.31, indexed 81.610 Apr 2026: close 35.04, indexed 81.017 Apr 2026: close 35.35, indexed 81.724 Apr 2026: close 32.58, indexed 75.301 May 2026: close 29.04, indexed 67.108 May 2026: close 28.11, indexed 65.015 May 2026: close 28.46, indexed 65.822 May 2026: close 30.29, indexed 70.029 May 2026: close 31.64, indexed 73.105 Jun 2026: close 31.59, indexed 73.012 Jun 2026: close 31.65, indexed 73.119 Jun 2026: close 31.8, indexed 73.526 Jun 2026: close 33.96, indexed 78.503 Jul 2026: close 34.27, indexed 79.210 Jul 2026: close 36.4, indexed 84.117 Jul 2026: close 35.97, indexed 83.124 Jul 2026: close 36.33, indexed 84.031 Jul 2026: close 35.72, indexed 82.507 Aug 2026: close 36.46, indexed 84.2 20 Jun 2026: sentiment 4720 Jun 2026: sentiment 4722 Jun 2026: sentiment 4822 Jun 2026: sentiment 4822 Jun 2026: sentiment 4822 Jun 2026: sentiment 4825 Jun 2026: sentiment 5026 Jun 2026: sentiment 4828 Jun 2026: sentiment 5101 Jul 2026: sentiment 5002 Jul 2026: sentiment 5203 Jul 2026: sentiment 5306 Jul 2026: sentiment 5310 Jul 2026: sentiment 5311 Jul 2026: sentiment 5311 Jul 2026: sentiment 5319 Jul 2026: sentiment 5320 Jul 2026: sentiment 5220 Jul 2026: sentiment 5220 Jul 2026: sentiment 5222 Jul 2026: sentiment 5222 Jul 2026: sentiment 5122 Jul 2026: sentiment 5123 Jul 2026: sentiment 5223 Jul 2026: sentiment 5123 Jul 2026: sentiment 5124 Jul 2026: sentiment 5130 Jul 2026: sentiment 53
13 Feb15 May07 Aug
Weekly close, indexedSentiment score
26-week price-15.8%latest close 36.46
Sentiment change+6available snapshot window
One-week response+2.1%Price confirming higher
Fair-value position-5.4%Near fair-value range
Sentiment-trend disagreement

News subjects

What is shaping the score

Earnings
Earnings772 stories · 100%

Source mix

Where the evidence comes from

0/100 independence
finance.yahoo.com772 stories · 100%

Recurring subjects

Subjects appearing most often

Current evidence
Total Revenue1Medical Sector1International Revenue1Infectious Diseases1Fda Approval1Earnings Per Share1Earnings Estimate1Earnings1Dividend Payments1Diagnostics1

Earlier readings

How the score has changed

50 is the neutral baseline
ConstructiveBalanced or withheldCautious

Source headlines

The news behind the score

Showing 1-2 of 2

Every row shows the public evidence used to understand the read. Direct company stories carry more weight than industry or sector context; duplicate coverage is consolidated before scoring.

#177Tone
finance.yahoo.comDirect company coverage

QIAGEN Receives U.S. FDA Clearance for First QIAstat-Dx Bloodstream Infection Panel

QIAstat-Dx BCID GPF Plus AMR Panel detects 20 pathogen targets and 10 antimicrobial resistance markers from positive blood cultures in about one hour FDA clearance marks QIAGEN's entry into U.S. bloodstream infection testing and establishes the first member of a planned QIAstat-Dx BCID panel family Bloodstream infections can rapidly progress to sepsis, a life-threatening condition affecting about 1.7 million adults annually in the U.S., underscoring the need for rapid detection GERMANTOWN, Md. & VENLO, Netherlands, August 10, 2026--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard:

Antimicrobial ResistanceDiagnosticsDividend PaymentsEarnings Per ShareFda ApprovalInfectious Diseases
Published
10 Aug 2026 20:05
Catalyst
Earnings
Evidence role
Direct company coverage
Duplicates
1 consolidated
#278Tone
finance.yahoo.comDirect company coverage

Understanding Qiagen (QGEN) Reliance on International Revenue

Have you assessed how the international operations of Qiagen (QGEN) performed in the quarter ended June 2026? For this diagnostic products maker, possessing an expansive global footprint, parsing the trends of international revenues could be critical to gauge its financial resilience and growth prospects. The global economy today is deeply interlinked, making a company's engagement with international markets a critical factor in determining its financial success and growth path. It has become essential for investors to comprehend how much a company relies on these foreign markets, as this unde

Consensus EstimateEarningsEarnings EstimateInternational RevenueMedical SectorTotal Revenue
Published
10 Aug 2026 13:15
Catalyst
Earnings
Evidence role
Direct company coverage
Duplicates
1 consolidated

How the page works

How to read the score

Tone is directional

It describes the weighted balance of qualifying headlines. A score of 50 can mean a balanced tape or that direction has been withheld for insufficient evidence; the status label distinguishes them.

Confidence is separate

Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme.

Price is confirmation

Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.

Classification, not prediction

The page describes completed evidence available at the stated time. It is research context, not a forecast, recommendation, target or execution instruction.

Evidence context